Next Data Milestone for Ph 1 SENTI-202 Study of SENTI-202 in AML Expected Q4 2025
“Our team has continued to advance SENTI-202’s clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML at the RP2D. Additionally, we recently received Orphan Drug Designation for SENTI-202 and bolstered the leadership and expertise of our team, welcoming new key members to our Scientific Advisory Board and our Board of Directors,” commented Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences. “Looking ahead, we are focused on growing our pipeline opportunities to deliver transformative therapies to patients with currently limited options and, importantly, expect to release additional efficacy and durability data from our ongoing Phase 1 study before the end of the year, representing a significant milestone for our lead program.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo